BRAF and neoplasm: In addition, MEK inhibitors such as trametinib and cobimetinib target downstream elements of the MAPK pathway, offering a broader impact by affecting both tumor and normal cells, unlike BRAF inhibitors which only target mutated tumor cells [24, 25].